Injectable nanomaterials for drug delivery: Carriers, targeting moieties, and therapeutics

• Published in: European journal of pharmaceutics and biopharmaceutics Vol. 84; no. 1; pp. 1 - 20
• Main Authors: Webster, David M., Sundaram, Padma, Byrne, Mark E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2013
• Subjects: Animals; Clinical Trials as Topic - methods; Drug Carriers - administration & dosage; Drug delivery carriers; Drug Delivery Systems - methods; Humans; Injectable nanoparticles; Injections; Liposomes; Nanocarriers; Nanostructures - administration & dosage; Neoplasms - diagnosis; Neoplasms - drug therapy; Targeting moieties; Therapeutics; Targeting moieties; Injectable nanoparticles; Nanocarriers; Drug delivery carriers; Therapeutics
• ISSN: 0939-6411; 1873-3441
• DOI: 10.1016/j.ejpb.2012.12.009

Generalized nanomedicine carrier. Structure composed of a core material containing both a hydrophobic and hydrophilic region, surface modifiers, and therapeutic payload. Therapeutics such as nucleic acids, proteins/peptides, vaccines, anti-cancer, and other drugs have disadvantages of low bio-availability, rapid clearance, and high toxicity. Thus, there is a significant need for the development of efficient delivery methods and carriers. Injectable nanocarriers have received much attention due to their vast range of structures and ability to contain multiple functional groups, both within the bulk material and on the surface of the particles. Nanocarriers may be tailored to control drug release and/or increase selective cell targeting, cellular uptake, drug solubility, and circulation time, all of which lead to a more efficacious delivery and action of therapeutics. The focus of this review is injectable, targeted nanoparticle drug delivery carriers highlighting the diversity of nanoparticle materials and structures as well as highlighting current therapeutics and targeting moieties. Structures and materials discussed include liposomes, polymersomes, dendrimers, cyclodextrin-containing polymers (CDPs), carbon nanotubes (CNTs), and gold nanoparticles. Additionally, current clinical trial information and details such as trial phase, treatment, active drug, carrier sponsor, and clinical trial identifier for different materials and structures are presented and discussed.